Evidence map›Paper›PMID 34646607›Full record

ReviewCureus2021

Correlation of Coronary Artery Disease and Left Ventricular Hypertrophy.

Khizer Khalid, Jaskamal Padda, Dina Ismail, Muhammad Abdullah, Dhriti Gupta, Roshini Pradeep, Warda Hameed, Ayden Charlene Cooper, Gutteridge Jean-Charles

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Metformin Attenuates Cardiac HypertrophyFrontiers in pharmacology · 2022
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Khizer KhalidInternal Medicine, Jean-Charles (JC) Medical Center, Orlando, USA.
Jaskamal PaddaInternal Medicine, Jean-Charles (JC) Medical Center, Orlando, USA.
Dina IsmailInternal Medicine, Jean-Charles (JC) Medical Center, Orlando, USA.
Muhammad AbdullahInternal Medicine, Jean-Charles (JC) Medical Center, Orlando, USA.
Dhriti GuptaInternal Medicine, Jean-Charles (JC) Medical Center, Orlando, USA.
Roshini PradeepInternal Medicine, Jean-Charles (JC) Medical Center, Orlando, USA.
Warda HameedInternal Medicine, Jean-Charles (JC) Medical Center, Orlando, USA.
Ayden Charlene CooperInternal Medicine, Jean-Charles (JC) Medical Center, Orlando, USA.
Gutteridge Jean-CharlesInternal Medicine, Jean-Charles (JC) Medical Center, Orlando, USA.
Charleston Area Medical Center · USOrlando Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic heart disease (IHD) is the leading cause of death worldwide, and it is defined as an imbalance between myocardial oxygen supply and demand. Coronary artery disease (CAD) and left ventricular hypertrophy (LVH) are two common causes of IHD that independently result in myocardial ischemia. CAD decreases myocardial blood and oxygen supply whereas LVH increases myocardial oxygen demand. The coexistence of both CAD and LVH results in a significant increase in oxygen demand while simultaneously lowering oxygen supply. Since hypertension is a shared predisposing condition for both CAD and LVH, the left ventricular (LV) mass on noninvasive echocardiography can reflect on the severity of coronary artery stenosis. In clinical practice, it can help physicians decide whether to perform invasive cardiac catheterization to visualize the extent of the coronary block. Although, both CAD and LVH are directly proportional to mortality risk, the addition of eccentric LVH can further increase morbidity and mortality due to myocardial infarction. Therefore, the latest management of both the acute and chronic phases of CAD places an increased emphasis on controlling the predisposing factors to prevent or reverse LVH. For example, angiotensin-converting enzyme inhibitors and diuretics reduce LV mass by lowering the cardiac preload and afterload. This article aims to investigate the deleterious effects of the collaboration between CAD and LVH, establish a causal relationship, and explore the new prevention and management strategies.

Indexed as

cad: coronary artery diseaseconcentriceccentricihdleft ventricular hypertrophy (lvh)myocardial infarction

Identifiers

PMID34646607
PMCPMC8479854
OpenAlexW3197603848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.